Completed PHASE3 INTERVENTIONAL NCT00150267

A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension

Sponsor: Pfizer

Conditions Glaucoma, Open-Angle Ocular Hypertension

Interventions Xalacom

Updated 6 times since 2017 Last updated: Nov 4, 2008 Started: Feb 28, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Glaucoma, Open-Angle and Ocular Hypertension and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aire Sur Adour, France , Alkmaar, Netherlands , Almería, Spain , Antwerp, Belgium , Athens, Greece , Badalona, Spain , Barcelona, Spain , Bilbao, Spain , Birmingham, United Kingdom , Bologna, Italy and 62 more locations